CMH :: Clinical and Molecular Hepatology

REVIEW Pathologic differential diagnosis of metastatic carcinoma in the liver
The liver is one of the most common sites to which malignancies preferentially metastasize. Although a substantial number of liver malignancies are primary tumors, including hepatocellular carcinoma and intrahepatic cholangiocarcinoma, the metastasis of carcinomas to the liver i...

REVIEW Radiomics and radiogenomics of primary liver cancers
Concurrent advancements in imaging and genomic biomarkers have created opportunities to identify non-invasive imaging surrogates of molecular phenotypes. In order to develop such imaging surrogates radiomics and radiogenomics/imaging genomics will be necessary; there has been co...

ORIGINAL ARTICLE Direct-acting antivirals-based therapy decreases hepatic fibrosis serum biomarker microfibrillar-associated protein 4 in hepatitis C patients
Background/Aims: An estimated 80 million people worldwide are infected with viremic hepatitis C virus (HCV). Even after eradication of HCV with direct acting antivirals (DAAs), hepatic fibrosis remains a risk factor for hepatocarcinogenesis. Recently, we confirmed the applicabil...

ORIGINAL ARTICLE Association between hepatic steatosis and the development of hepatocellular carcinoma in patients with chronic hepatitis B
Background/Aims: Nonalcoholic fatty liver disease (NAFLD) is becoming a worldwide epidemic, and is frequently found in patients with chronic hepatitis B (CHB). We investigated the impact of histologically proven hepatic steatosis on the risk for hepatocellular carcinoma (HCC) in...

Current Issue

Volume 25(1); Mar 2019

Volume 24(4); December 2018

Volume 24(3); September 2018

Volume 24(2); June 2018

Volume 24(1); March 2018

Reviews

Recent research trends and updates on nonalcoholic fatty liver disease

Jeong-Ju Yoo, Won Kim, Moon Young Kim, Dae Won Jun, Sang Gyune Kim, Jong-Eun Yeon, Jin Woo Lee, Yong Kyun Cho, Sang Hoon Park, Joo Hyun Sohn, On behalf of the Korean Association for the Study of the Liver (KASL)-Korea Nonalcoholic fatty liver Study Group (KNSG)

Clin Mol Hepatol.2019;25(1):1-11. Published online August 8, 2018
DOI: https://doi.org/10.3350/cmh.2018.0037

Cited By 2

Pathologic differential diagnosis of metastatic carcinoma in the liver

Jeong Hwan Park, Jung Ho Kim

Clin Mol Hepatol.2019;25(1):12-20. Published online October 5, 2018
DOI: https://doi.org/10.3350/cmh.2018.0067

Radiomics and radiogenomics of primary liver cancers

Woo Kyoung Jeong, Neema Jamshidi, Ely Richard Felker, Steven Satish Raman, David Shinkuo Lu

Clin Mol Hepatol.2019;25(1):21-29. Published online November 16, 2018
DOI: https://doi.org/10.3350/cmh.2018.1007

Discussion on critical points for a tailored therapy to cure hepatitis C virus infection

Nadia Marascio, Angela Quirino, Giorgio Settimo Barreca, Luisa Galati, Chiara Costa, Vincenzo Pisani, Maria Mazzitelli, Giovanni Matera, Maria Carla Liberto, Alfredo Focà, Carlo Torti

Clin Mol Hepatol.2019;25(1):30-36. Published online January 23, 2019
DOI: https://doi.org/10.3350/cmh.2018.0061

Editorials

Biomarker microfibril-associated glycoprotein 4 for non-invasive diagnosis and therapeutic evaluation of hepatic fibrosis in patients with hepatitis C

Young Woo Eom, Soon Koo Baik

Clin Mol Hepatol.2019;25(1):37-39. Published online December 11, 2018
DOI: https://doi.org/10.3350/cmh.2018.1011

Can hepatic steatosis really promote hepatitis B viral hepatocarcinogenesis? The jury is out on.

Won Kim

Clin Mol Hepatol.2019;25(1):40-41. Published online December 28, 2018
DOI: https://doi.org/10.3350/cmh.2018.0101

Original Articles

Direct-acting antivirals-based therapy decreases hepatic fibrosis serum biomarker microfibrillar-associated protein 4 in hepatitis C patients

Christian Mölleken, Maike Ahrens, Anders Schlosser, Julia Dietz, Martin Eisenacher, Helmut E. Meyer, Wolff Schmiegel, Uffe Holmskov, Christoph Sarrazin, Grith Lykke Sorensen, Barbara Sitek, Thilo Bracht

Clin Mol Hepatol.2019;25(1):42-51. Published online November 19, 2018
DOI: https://doi.org/10.3350/cmh.2018.0029

Cited By 1

Association between hepatic steatosis and the development of hepatocellular carcinoma in patients with chronic hepatitis B

Yun Bin Lee, Yeonjung Ha, Young Eun Chon, Mi Na Kim, Joo Ho Lee, Hana Park, Kwang-il Kim, Soo-Hwan Kim, Kyu Sung Rim, Seong Gyu Hwang

Clin Mol Hepatol.2019;25(1):52-64. Published online October 23, 2018
DOI: https://doi.org/10.3350/cmh.2018.0040

Efficacy of L-carnitine on ribavirin-induced hemolytic anemia in patients with hepatitis C virus infection

Shinya Sato, Kei Moriya, Masanori Furukawa, Soichiro Saikawa, Tadashi Namisaki, Mitsuteru Kitade, Hideto Kawaratani, Kosuke Kaji, Hiroaki Takaya, Naotaka Shimozato, Yasuhiko Sawada, Kenichiro Seki, Koh Kitagawa, Takemi Akahane, Akira Mitoro, Yasushi Okura, Junichi Yamao, Hitoshi Yoshiji

Clin Mol Hepatol.2019;25(1):65-73. Published online February 25, 2019
DOI: https://doi.org/10.3350/cmh.2018.0070

Safety margin of embolized area can reduce local recurrence of hepatocellular carcinoma after superselective transarterial chemoembolization

Kittipitch Bannangkoon, Keerati Hongsakul, Teeravut Tubtawee, Teerha Piratvisuth

Clin Mol Hepatol.2019;25(1):74-85. Published online February 28, 2019
DOI: https://doi.org/10.3350/cmh.2018.0072

Letter to the Editor

Biochemical profile in an infant with neonatal hemochromatosis shows evidence of impairment of mitochondrial long-chain fatty acid oxidation

Karina Lucio de Medeiros Bastos, Caio Robledo Quaio, Fabiana Roberto Lima, Iana Manuelle Araújo, Candice Alves Tavares Araújo, Flávia Balbo Piazzon, Ismael Dale Cotrim Guerreiro da Silva, Gabriel Nuncio Benevides, Ana Cristina Tannuri, Uenis Tannuri, Ramiro Anthero Azevedo, Chong Ae Kim

Clin Mol Hepatol.2019;25(1):86-91. Published online August 28, 2018
DOI: https://doi.org/10.3350/cmh.2018.0005

Cited By 1

The Korean Association for the Study of the Liver